Report error Found 4679 of ic50 data for polymerid = 470
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 2nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 2nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3.70nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3.70nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3.70nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3.70nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4.20nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4.20nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4.40nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4.40nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4.60nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 4.60nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5.20nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5.20nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5.30nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5.30nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5.5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5.5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5.5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5.5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5.70nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK a...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Human)
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 5.70nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
